Group 1: Company Overview and Strategy - Chongqing Boteng Pharmaceutical Technology Co., Ltd. was established in 2005, initially focusing on serving large clients like Johnson & Johnson in the CMO industry [1] - The company adopted a "big client" strategy to optimize resource allocation and gradually expanded its client base and product lines [1] - In 2014, the business development strategy was adjusted to include both large and small clients, which remains a key focus for the company [1] Group 2: Shareholding Structure - The actual controllers of the company are three individuals, collectively holding approximately 44% of the shares [1] - A transaction is in progress for QING SHAO to acquire 6.47% of the shares, which will make the fund under China Merchants Capital a strategic shareholder with over 5% ownership [2] Group 3: Financial Management and Risk - The company is aware of the high pledge ratio of major shareholders and is taking measures to manage associated risks [2] - A price adjustment mechanism is in place with overseas clients to mitigate the impact of significant exchange rate fluctuations [2] - The company is cautious about using foreign exchange hedging tools due to past losses experienced by other firms [2] Group 4: Production Capacity and Financial Performance - The overall capacity utilization rate for the company's three bases was not very high last year, with Long寿 and Jiangxi Dongbang bases at approximately 60% and Zhejiang Shangyu base at about 40% [2] - The company reported strong operating cash flow, marking the best performance in the past three years, with high-quality accounts receivable from multinational pharmaceutical clients [3] - Capital expenditures will be reduced this year, focusing only on fundraising projects without significant additional investments [3]

Group 1: 2017 Performance Overview - The company's 2017 revenue is expected to decline by 0%-10%, while net profit attributable to shareholders is projected to decrease by 30%-40% due to significant fluctuations from two major clients [1] - Despite the revenue decline, sales growth from other clients helped maintain overall revenue stability in 2017 [1] - The profit decline is attributed to increased financial expenses, operating costs, and fixed asset depreciation [1] Group 2: 2018 Business Focus - In 2018, the company will focus on three key business areas: API projects, the Chinese market, and CRO services [2] - The company secured approximately 20 million in orders from Chinese clients in 2017 and anticipates further growth in this area due to increased domestic client visits [2] - Following the acquisition of J-STAR Research in 2017, the company plans to strengthen its CRO business and establish a J-STAR China division in Shanghai [2] Group 3: Future Plans and Strategies - The company is currently evaluating potential investors for its private placement, which is based on market price inquiries [3] - The CMO project for biopharmaceuticals is expected to launch in the first half of 2018, with a construction period of three years [3] - The introduction of China Merchants Capital as a strategic investor aims to stabilize shareholder reductions and improve the company's equity and governance structure [3] Group 4: Business Model and Strategy - The company aims to develop a "pharmaceutical service platform" strategy, focusing on both chemical and biological drugs [3] - Future plans include extending services from CMO to CRO, creating a comprehensive end-to-end service system [3]

Group 1: Revenue and Client Concentration - In 2016, the revenue from the top two clients, including Johnson & Johnson, accounted for approximately 70% of total revenue. It is expected to decrease to around 50% in 2017, with a goal to limit single client revenue concentration to no more than 25% in the future [1] Group 2: CRO Business Development - The company has a dedicated CRO team, primarily based in the US and Shanghai, with an addition of approximately 100 R&D personnel last year. The company plans to continue expanding its R&D team to enhance CRO capabilities [1] Group 3: Market Expansion and Performance - The company is pursuing an end-to-end model in the pharmaceutical service platform, with significant growth in the domestic market observed in the first two months of the current year, indicating a potential breakthrough year [2] Group 4: Financial Management and Risks - The company is focused on reducing the high pledge ratio of shares held by the three actual controllers, as part of their core work this year, following previous investments funded through share pledges [2] - The majority of the company's settlements are in USD, and there have been exchange losses due to currency fluctuations. The company is researching hedging measures to mitigate exchange rate risks [2] Group 5: Product Pipeline - The company has a pipeline of hundreds of projects, including commercialized products and those in clinical stages, with a focus on diabetes combined with heart failure drugs, anti-tumor drugs, and BTK inhibitors [3]

证券代码：300363 证券简称：博腾股份 重庆博腾制药科技股份有限公司 投资者关系活动记录表 编号：00320171114 | --- | --- | --- | |-------------------------|-----------------------------|---------------------------------------------------------------------------| | 投资者关系活动类别 \n | ■特定对象调研 \n■现场参观 | □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 | | | □其他 | | | | | 方正证券（香港）有限公司：蔡静芳 | | | | 国泰证券投资信托股份有限公司：黄馨慧 | | | | 台新证券投资信托股份有限公司：游欣颖 | | | 元大投信：莊慧君 | | | 参与单位名称及人员姓名 | 中泰证券股份有限公司：赵磊 | 富邦证券投资信托股份有限公司：高晧欣 北京正格资本管理有限公司：张诚、黎力 | | | 国信证券：杨辉 | 西南证券：段波、欧勇、李勇、李斯坦 | | | 中国证 ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00920200922 | --- | --- | --- | --- | |---------------------|--------------------------|------------------------------------------|------------------------------------------------------| | | | | | | | | ■特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活 动类别 | | □新闻发布会 □路演活动 | | | | □现场参观 | □电话通讯 | | | | □其他 | | | | 参与单位名称 | | 财通基金：金梓才、张胤、徐博 | | | 及人员姓名 | 国盛证券：张金洋、汪文沁 | | | | 时间 | 2020 年 9 月 | 日 | | | | | | | | | 地点 公司重庆研发中心 | | | | 上市公司接待 | 居年丰 董事长兼总经理 | | | | 人员姓名 | ...

证券代码：300363 证券简称：博腾股份 | --- | --- | --- | |--------------|---------------------------------------------------------|--------------------------------------------------------| | | | 编号：00520190911 \n█特定对象调研 □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活 | | □新闻发布会 □路演活动 | | 动类别 | █现场参观 | □电话通讯 | | | □其他 | （请文字说明其他活动内容） | | | 西南证券 何治力、陈进 | | | | 万联证券 郑伟光 | | | | 国都证券 王义 | | | 参与单位名称 | 国开证券 周成娟 | | | 及人员姓名 | 富邦证券 蒋栋 金信基金 杨仁眉、程可 博远基金 谭飞 | | | | 域秀资本 涂翡斐 | | | 时间 2019 | 年 09 月 11 | | | 地点 公司 | 2-1 会议室 | | | 上市公司接待 | 皮薇 | ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------|--------------------------------------------------------| | | | | 编号：00220190523 | | | █特定对象调研 □分析师会议 | | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活 | □新闻发布会 □路演活动 | | | | 动类别 | █现场参观 | □电话通讯 | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 诺安基金管理有限公司 重庆泰合毓涧科技有限公司 北京厚石基金管理有限公司 | 史高飞，李雷 刘培林，刘永维 曾 ...

证券代码：300363 证券简称：博腾股份 重庆博腾制药科技股份有限公司 投资者关系活动记录表 编号：01120180625 | --- | --- | |-----------------------------|-----------------------------------------------------------------------| | | | | | 特定对象调研 □ 分析师会议 | | | □ 业绩说明会 | | 投资者关系活动类别 | □ 路演活动 | | | | | | | | | 汇丰银行：赵智捷，樊嘉蕾，温馨 | | 参与单位名称及人员姓名 | 博裕资本：陈云章 Overlook Investments Limited ）：邱中伟 | | | | | 时间 | 25 日 | | 地点 上市公司接待人员姓名 | 公司二楼会议室 董事会秘书陶荣，副总经理喻咏梅，证券事务代表皮薇，董事 | | | 一、公司基本情况及行业情况介绍。 | | | 二、公司和投资者主要交流情况如下： | | | ：作为投资者，应该如何跟踪公司的业务？ | | | ：这是很多投资者都关注的问题。博腾以 ...

证券代码：300363 证券简称：博腾股份 重庆博腾制药科技股份有限公司 投资者关系活动记录表 编号：01020180606 | --- | --- | --- | |---------------------------------------------------------|--------------------------------|--------------------------------------------------------| | | | | | | ■特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | 参与单位名称及人员姓名 | 长城证券:陈晨 | | | 时间 | 2018 年 06 月 06 日 | | | 地点 公司二楼会议室 | | | | 上市公司接待人员姓名 证券事务代表皮薇，董事会办公室陈靓 | | | | | 公司和投资者主要交流情况如下： | | | | | | | | Q1 的市场预期如何？ | ：索非布韦在发达 ...

证券代码：300363 证券简称：博腾股份 重庆博腾制药科技股份有限公司 投资者关系活动记录表 编号：00920180529 | --- | --- | --- | |------------------------|----------------------------------------|-------------------------------------------------------------| | | ■特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | 参与单位名称及人员姓名 | 招商证券:李勇剑,李点典 华富基金:翁海波 | | | | | | | 时间 | 2018 年 05 月 29 日 | | | 地点 公司二楼会议室 | | 董事长、总经理居年丰，证券事务代表皮薇，董事会办公室陈 | | 上市公司接待人员姓名 | 靓 | | | | | | | | 公司和投资者主要交流情况如下： | | | | Q1 ：公司 BD | （业务开 ...